Skip to main content

Joshua D. Fox


[email protected]



Josh advises entrepreneurs to help them build their businesses and complete successful fundraising transactions and exit events.

Josh’s practice focuses on representing founders and start-ups. He serves as outside corporate counsel to his clients, functioning as their general counsel throughout the lifecycle of their businesses to help them develop effective legal and business strategies, solve problems, and complete deals that advance their business goals. He regularly advises clients regarding company formation and early-stage legal issues, financings (including angel, venture capital. and strategic investments) and mergers and acquisitions.

Josh typically works with companies in the life sciences industry — drug development, devices, diagnostics and tools — and in the technology sector, including digital health, software, and technology-enabled services. He has helped numerous clients, including the following, to grow and thrive:  

  • Aquinnah Pharmaceuticals
  • Asimov
  • Axoft
  • Bilayer Therapeutics
  • Droplette
  • Hopewell Therapeutics
  • InGel Therapeutics
  • MediSix Therapeutics
  • NanoView Biosciences
  • NextGen Jane
  • New Equilibrium Biosciences
  • PanTher Therapeutics
  • Quaise Energy
  • Stemloop
  • Suono Bio
  • Syntis Bio
  • Teal Bio
  • Verseau Therapeutics

In addition to counseling entrepreneurs and emerging companies, Josh represents investors, including venture capital firms and foundations, in the investments that they make. Notable investor-side clients include Lightstone Ventures and The Mark Foundation for Cancer Research.

He frequently speaks on topics related to entrepreneurship, financing, exit strategies, and best practices for businesses.

Josh also maintains an active pro bono practice, is involved in the firm’s hiring activities and is a lecturer at the Boston University School of Law, where he teaches a class on venture capital financings that he created. 


The Mintz and Mergermarket report on recent M&A activity in the life sciences sector examines deal drivers and companies’ post-closing integration experiences.
Read more
Read less

News & Press

News Thumbnail
Carta quoted Member Joshua Fox about the state of the venture capital environment and the creative solutions startups are leaning on to avoid a down round.
News Thumbnail
Mintz's sponsorship and involvement with the MassNextGen Initiative was highlighted in a press release issued by the Massachusetts Life Sciences Center.
Press Release Thumbnail
BOSTON – Mintz has entered into an exclusive partnership with Nucleate Boston, providing the nonprofit organization with legal support for its 2023 Activator Program.
News Thumbnail
Mintz Member Joshua Fox spoke to the Wall Street Journal about what's ahead for biotech startups and venture capitalists following a difficult year.
News Thumbnail
Mintz Member Joshua Fox spoke to Forbes about the logistics of Shark Tank and how deal terms develop after filming.
Press Release Thumbnail
Mintz has guided long-standing client Asimov in its $200 million fundraising aimed to scale the company’s tools and services business in biologics, cell/gene therapies, and RNA.
Press Release Thumbnail
Mintz represented Axoft, a neurotechnology company, in its $8 million seed round led by The Engine, a venture firm spun out of MIT that invests in early-stage Tough Tech companies.
Press Release Thumbnail
Mintz took lead role for long-term client NanoView Biosciences in its sale to Unchained Labs, a portfolio company of The Carlyle Group. NanoView, through its ExoView technology, characterizes exosomes and the company’s LentiView platform complements Unchained Labs’ tools for gene therapy researchers working with lentivirus, which is an immunodeficiency virus that causes AIDS.
Press Release Thumbnail
In New Report, Dealmakers across the Life Sciences Industry Identify Top Deal Drivers, Successful Integration Strategies, and More.
An article published by The American Lawyer highlighted the arrival of Joshua Fox in Boston and Stephen Osborn in San Francisco as Members in Mintz’s Corporate group.

The article noted that “Osborn and Fox are the latest hires in Mintz’s growing corporate practice, which also had two notable hires in March. The Boston-based firm is enjoying record revenue and profit highs after four straight years of growth.”
Read less

Events & Speaking

Recognition & Awards

  • Chambers USA: Nationwide - Start Ups and Emerging Companies (2023)
  • Boston Magazine: Top Lawyers – Corporate Law (2021)
  • Conservation Law Foundation, Legal Food Hub: Distinguished Service Award (2019)
  • The Legal 500 United States: Recommended for Finance: Capital Markets: Equity Offerings: Advice to Managers (2016)
  • Boston Magazine: New England Super Lawyers Rising Stars (2008, 2010 – 2016)
  • Boston Bar Association, Lawyers Committee for Civil Rights Under Law: Civil Rights Recognition Award (2010)
  • Phi Beta Kappa
Read less


  • Past Member, Board of Visitors, D’Amore-McKim School of Business, Northeastern University
  • Past President and Member, Board of Directors, Tufts Lawyers Association
  • Past Mentor, BUILD
  • Past Member, Leadership Council, Dana-Farber Cancer Institute
  • Past Member, Alumni Council, Tufts University
Read less

Joshua D. Fox